SCHEMBL21597513

SCHEMBL21597513

CCOC(=O)C1CCCc2cc(NC(=O)C3CC3)sc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.53
ALOX15 P16050 1/20 0.53
ALDH1A1 P00352 7/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
MAPT P10636 8/20 0.46
GAA P10253 5/20 0.46
POLB P06746 2/20 0.46
HIF1A Q16665 1/20 0.46
LMNA P02545 2/20 0.43
KMT2A Q03164 6/20 0.42
MEN1 O00255 4/20 0.42
NPSR1 Q6W5P4 2/20 0.42
PRNP P04156 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HPGD P15428 4/20 0.41
MAPK1 P28482 1/20 0.41
RECQL P46063 1/20 0.40
KDM4E B2RXH2 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21603887 0.85 TP53 (0.44) TP53ALOX15ALDH1A1RAB9ASMN1; SMN2
SCHEMBL21597597 0.82 TP53 (0.40) TP53ALOX15ALDH1A1RAB9ASMN1; SMN2
SCHEMBL21597595 0.76 TP53 (0.54) TP53ALOX15ALDH1A1RAB9ASMN1; SMN2
SCHEMBL21597670 0.73 MAPT (0.47) TP53ALOX15ALDH1A1RAB9ASMN1; SMN2
SCHEMBL10747390 0.72 MAPT (0.46) ALDH1A1SMN1; SMN2MAPTGAAPOLB
SCHEMBL21597739 0.70 MAPT (0.47) TP53ALOX15ALDH1A1RAB9ASMN1; SMN2
SCHEMBL8291574 0.69 NPC1 (0.47) TP53ALOX15ALDH1A1RAB9ASMN1; SMN2
SCHEMBL21597774 0.69 CNR2 (0.45) TP53ALOX15ALDH1A1MAPTGAA
SCHEMBL11458476 0.66 TLR4 (0.44) ALDH1A1SMN1; SMN2MAPTGAALMNA
SCHEMBL19643853 0.65 P2RX7 (0.51) ALDH1A1SMN1; SMN2MAPTGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 TP53 2515/4885ALOX15 217/4885ALDH1A1 233/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 TP53 2515/4885ALOX15 217/4885ALDH1A1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.